BioCentury
ARTICLE | Company News

HGSI announces Takeda target selection

March 27, 2001 8:00 AM UTC

Human Genome Sciences said partner Takeda Chemicals has identified about 100 protein targets that it will use in small molecule and antibody drug development programs in the areas of diabetes, cardiovascular disease, bone and joint diseases, central nervous system disorders, urogenital diseases and allergy. Takeda spent six years following the initiation of the deal in 1995 combing HGSI's database of full length mRNAs and validating targets to make its selections. HGSI will receive milestones and mid-to-high single digit royalties on products developed. ...